<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2012072410377N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2012-11-16</date_registration>
      <primary_sponsor>Baryj Essence Pharmaceutical Company</primary_sponsor>
      <public_title>Comparison the effect of Aloe Vera and Benzydamine hydrochloride mouth rinses on mucositis caused by radiation</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of aloe vera mouthwash and and Benzydamine Hydrochloride mouthwash on radiation induced mucositis in patients with head and neck cancer</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2012-07-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>26</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/10888</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Other design features: Process of randomization: Pharmaceutical Company ” Barij Essence” will be packaged the mouth rinses into two quite similar bottles and will be send them to School of Dentistry, Tehran University of Medical Sciences. Two non-beneficiaries will label the bottles and then will give them to the Researcher. Without being aware about the mouth rinses ingredients, and just based on the ordering (numbers) The researcher will give the bottles to the patients. Patients will not aware about the content of the rinses either. In the consent form it is indicated that Rinses contain Benzydamine or Aloe Vera extract. Neither the researcher, nor the patients nor the statistical analyzer will be aware of the type of mouth rinses.</study_design>
      <phase>2</phase>
      <hc_freetext>Mucositis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention: Aloe vera mouth rinse, chemical composition: Aloe vera gel 100%, concentration of 0.0009% Blue color Brilliant Blue, concentration of 0.0006% yellow color Tarterazine, manufacturer: Baryj Essence Pharmaceutical Company- During 6 weeks of Radiotherapy and up to 1 week after it, patients are asked to use 5 cc of mouth rinse 3 times a day, each time for 2 minutes and are avoid from eating and drinking for 30 minutes after using the mouth rinse. Intervention 2: Control: Benzydamine hydrochloride Mouth rinse, chemical composition: Benzydamine hydrochloride 0/15 %, manufacturer: pharmaceutical company Behvazan, brand: Behvazan 0/15% - During 6 weeks of Radiotherapy and up to 1 week after it, patients are asked to use 5 cc of mouth rinse 3 times a day, each time for 2 minutes and are avoid from eating and drinking for 30 minutes after using the mouth rinse.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Doctor Arash Mansourian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Oral Medicine Department, school of Dentistry Tehran University of Medical Sciences، next to nuclear energy organization ، North Kargar Street، Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 8835 1152</telephone>
        <email>aMansourian@tums.ac.ir</email>
        <affiliation>School of Dentistry Tehran University of Medical Sciences, oral medicine Department</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Doctor Mahnaz Saheb Jamee</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Oral Medicine Department, school of Dentistry Tehran University of Medical Sciences, next to nuclear energy organization , North Kargar Street,Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 8835 1152</telephone>
        <email>sahebjam@sina.tums.ac.ir</email>
        <affiliation>School of Dentistry Tehran University of Medical Sciences, oral medicine Department</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: Minimum age: 18 years, diagnosed cancer in the head and neck region, the minimum therapeutic dose of 50 Gy, oral cavity is placed in the radiation field, the patient's ability to cooperate and use medications as directed. Exclusion criteria: Patients with a history of cancer treatment during the last year, patients with a history of food allergy, oral lesions including active infection, mouth ulcers before starting the radiation therapy, lack of patient willingness and cooperation to participate in the study.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L58.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acute radio dermatitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention: Aloe vera mouth rinse, chemical composition: Aloe vera gel 100%, concentration of 0.0009% Blue color Brilliant Blue, concentration of 0.0006% yellow color Tarterazine, manufacturer: Baryj Essence Pharmaceutical Company- During 6 weeks of Radiotherapy and up to 1 week after it, patients are asked to use 5 cc of mouth rinse 3 times a day, each time for 2 minutes and are avoid from eating and drinking for 30 minutes after using the mouth rinse.</i_keyword>
      <i_keyword>Control: Benzydamine hydrochloride Mouth rinse, chemical composition: Benzydamine hydrochloride 0/15 %, manufacturer: pharmaceutical company Behvazan, brand: Behvazan 0/15% - During 6 weeks of Radiotherapy and up to 1 week after it, patients are asked to use 5 cc of mouth rinse 3 times a day, each time for 2 minutes and are avoid from eating and drinking for 30 minutes after using the mouth rinse.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Mucositis grade. Timepoint: From Starting of radiation therapy, weekly during 6 weeks of treatment and 1 week after treatment. Method of measurement: questionnaire based on the Mucositis grade rating items from the World Health Organization (WHO).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Mouth soreness. Timepoint: From starting of radiation therapy, weekly during 6 weeks of treatment and 1 week after treatment. Method of measurement: Questionnaire (Asking from patient).</sec_outcome>
      <sec_outcome>Ulcer. Timepoint: From starting of radiation therapy, weekly during 6 weeks of treatment and 1 week after treatment. Method of measurement: Questionnaire (Observation).</sec_outcome>
      <sec_outcome>Disability to swallowing solid food. Timepoint: From starting of radiation therapy, weekly during 6 weeks of treatment and 1 week after treatment. Method of measurement: Questionnaire (Asking from patient).</sec_outcome>
      <sec_outcome>Disability to alimentation. Timepoint: From starting of radiation therapy, weekly during 6 weeks of treatment and 1 week after treatment. Method of measurement: Questionnaire (Asking from patient).</sec_outcome>
      <sec_outcome>Erythema. Timepoint: From starting of radiation therapy, weekly during 6 weeks of treatment and 1 week after treatment. Method of measurement: Questionnaire (Asking from patient and observation).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>Vice chancellor for research, school of Dentistry Tehran University of Medical Sciences</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Baryj Essence Pharmaceutical Company</source_name>
      <source_name>Vice chancellor for research, school of Dentistry Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-07-23</approval_date>
        <contact_name>Vice chancellor for research,Tehran University of Medical Sciences</contact_name>
        <contact_address>The Sixth Floor, central Organization of University, Keshavarz Blvd. Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
